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Aims: HTL0009936 is a selective M1 muscarinic receptor agonist in development for
cognitive dysfunction in Alzheimer's disease. Safety, tolerability and pharmacokinet-
ics and exploratory pharmacodynamic effects of HTL0009936 administered by con-
tinuous IV infusion at steady state were investigated in elderly subjects with below
average cognitive functioning (BACF).
Methods: Part A was a four-treatment open label sequential study in healthy elderly
investigating 10–83 mg HTL0009936 (IV) and a 24 mg HTL0009936 single oral dose.
Part B was a five-treatment randomized, double-blind, placebo and physostigmine
controlled cross-over study with IV HTL0009936 in elderly subjects with BACF.
Pharmacodynamic assessments were performed using neurocognitive and electro-
physiological tests.
Results: Pharmacokinetics of HTL0009936 showed dose-proportional increases in
exposure with a mean half-life of 2.4 hours. HTL0009936 was well-tolerated with
transient dose-related adverse events (AEs). Small increases in mean systolic blood
pressure of 7.12 mmHg (95% CI [3.99–10.24]) and in diastolic of 5.32 mmHg (95%
CI [3.18–7.47]) were noted at the highest dose in part B. Overall, there was sugges-
tive, but no definitive, positive or negative pharmacodynamic effects. Statistically sig-
nificant effects were observed on P300 with HTL0009936 and adaptive tracking
with physostigmine.
Conclusions: HTL0009936 showed well-characterized pharmacokinetics and single
doses were safe and generally well-tolerated in healthy elderly subjects. Due to phy-
sostigmine tolerability issues and subject burden, the study design was changed and
some pharmacodynamic assessments (neurocognitive) were performed at suboptimal
Charlotte Bakker MD and Samantha Prins MSc shared first authorship.
ISRCTN.org Identifier: ISRCTN12371179 (retrospective registration).
PI statement: The authors confirm that the PI for this paper is Geert Jan Groeneveld and that he had direct clinical responsibility for patients.
Received: 11 May 2020 Revised: 10 March 2021 Accepted: 16 March 2021
DOI: 10.1111/bcp.14872
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
© 2021 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
Br J Clin Pharmacol. 2021;1–11. wileyonlinelibrary.com/journal/bcp 1
drug exposures. Therefore no clear conclusions can be made on pharmacodynamic
effects of HTL0009936, although an effect on P300 is suggestive of central target
engagement.
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1 | INTRODUCTION
Alzheimer's Disease (AD) and Dementia with Lewy Body (DLB) are
the most common cause of dementia.1 Clinically, AD and DLB are
characterized by the progressive decline of cognitive functions.
Research has shown that AD is characterized by a significant and
progressive loss of cholinergic neurons, especially in the nucleus
basalis of Meynert, along with their cortically projecting axons,2 and
this cholinergic degeneration is correlated with cognitive decline.3,4
To date, no curative treatment is available and patients can only
benefit from symptomatic treatments, such as the acetylcholinester-
ase inhibitors (AChEIs) galantamine, donepezil and rivastigmine.5
However, the efficacy of treatment with AChEIs is moderate6–8 due
to only partial central inhibition of AChEIs9,10 and it often leads to
gastrointestinal side effects (e.g. nausea, vomiting and diarrhoea)
associated with increased activation of peripherally located musca-
rinic receptors, causing dose limitations and a significant burden for
patients.6–8
The cholinergic receptors comprise two broad classes; the
ionotropic nicotinic receptors and metabotropic muscarinic receptors.
The muscarinic receptors are a group of Class I G-protein-coupled
receptors (GPCRs) comprising five distinct sub-types, termed M1, M2,
M3, M4 and M5.
11 Drugs that selectively target specific muscarinic
receptor type(s) may enhance cognitive and behavioural function in
AD and DLB patients while minimizing the negative side-effects asso-
ciated with non-selective activation of all muscarinic receptor types, in
particular M2 and M3 receptors that have been predominantly linked
to the gastrointestinal and cardiovascular side effects.12 The musca-
rinic M1 receptor (M1 AChR) is predominant in the central nervous sys-
tem (CNS) and found to be expressed in the prefrontal cortex, striatum
and hippocampus. These brain areas are known to be associated with
cognitive processes.13,14 The M1 AChR is relatively well preserved in
AD and DLB patients.15,16 Drugs that selectively target M1 AChR could
be potential treatment for cognitive and behavioural dysfunction in
AD and DLB.12,17 Additionally, the effects of selective M1 AChR ago-
nists are independent of the existence of cholinergic tone in the CNS,
and their benefit may be sustained further into disease progression
than the benefit of cholinesterase inhibitors or M1 receptor-positive
allosteric modulators which rely on pre-synaptic cholinergic tone.
HTL0009936 ((S)-Ethyl 4-(4-[1-methylcyclobutylcarbamoyl]
piperidin-1-yl)azepane-1-carboxylate)18 is a potent and selective M1
AChR agonist that is currently under development for the symptom-
atic treatment of the cognitive symptoms of dementias including AD
and DLB. HTL0009936 has no detectable activity at M2 and M3
AChRs, and a seven-fold margin of functional selectivity over M4
AChR in vitro. It has been investigated in an oral solution formulation,
dosed at 1–175 mg in a phase I trial in young adults and elderly sub-
jects (in preparation). Pharmacokinetics (PK) of oral HTL0009936
showed a low oral bioavailability and a significant degree of variability
between subjects. In order to reduce this variability and to ensure
sustained exposure within the central nervous system (CNS) over the
period of cognitive testing, HTL0009936 was given as an intravenous
infusion in the current study.
This study was conducted in two parts. The aim of part A was to
evaluate the safety, tolerability and PK in elderly subjects in order to
identify a well-tolerated dosing regimen to take forward into part B,
and to determine the absolute oral bioavailability of HTL0009936. In
part B safety, tolerability, PK and exploratory PD of IV HTL0009936
were investigated in elderly subjects with below average cognitive
functioning (BACF). These subjects had no evidence of progressive
cognitive deterioration.
What is already known about this subject
• Degeneration of cholinergic neurons contributes to cog-
nitive dysfunction in Alzheimer's disease (AD).
• The M1 muscarinic receptor plays a key role in cognitive
function.
• The M1/M4 receptor agonist xanomeline showed efficacy
in AD but was withdrawn due to adverse effects. Selec-
tively targeting M1 receptors may be a more promising
approach to improve cognition without adverse events.
What this study adds
• The intravenously administered selective M1 mAChR
agonist HTL0009936 was well-tolerated by elderly sub-
jects up to doses of 83 mg.
• HTL0009936 showed dose-proportional exposures with
a half-life between 2.2 and 2.6 hours and modest
variability.
• No clear positive or negative effects could be detected
for both drugs due to study limitations.
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2 | METHODS
This study was approved by the medical ethics review board Stichting
Beoordeling Ethiek Biomedisch Onderzoek (BEBO, Assen, The
Netherlands) and was conducted according to the Dutch Act on
Medical Research Involving Human Subjects (WMO) and in compli-
ance with Good Clinical Practice (ICH-GCP) and the Declaration of
Helsinki.19
2.1 | Trial design and subjects
This study consisted of part A and B. Part A was an initial pilot phase
administering 0.1 and 1 mg HTL009936 given as a 30 minute infusion
followed by a four-treatment open label sequential study with IV and
oral administration of HTL0009936 in elderly subjects (n = 10). The
objectives of part A were to evaluate the safety, tolerability and
the PK profile of HTL0009936, to identify a well-tolerated dosing reg-
imen for part B and to determine the absolute oral bioavailability of
HTL0009936. Part B was a five-treatment randomized, double-blind,
placebo and positive comparator-controlled crossover study with IV
HTL0009936 in elderly subjects with BACF (n = 33). The objectives
of part B were to evaluate safety, tolerability and PK of HTL0009936
and to evaluate PD in comparison to placebo and a positive
comparator.
In both parts A and B, subjects were healthy male and female
elderly (65+ years) with a maximum blood pressure of 140/90 mm
Hg and a heart rate between 45–100 bpm at screening. Use of antihy-
pertensive drugs was not allowed. Consumption of alcohol and
caffeine-containing products, use of nicotine-containing products
and drugs influencing CYP3A4 and CYP2D6 activity were not allowed
prior to and during the study. Subjects were defined as intermediate
(IM) or extensive (EM) CYP2D6 metabolizers based on their genotype
and were excluded if they were poor or ultra-rapid metabolizers in
order to minimize variability in the steady state plasma concentrations
in part B.
Subjects in part B functioned below average on tests of cognitive
functioning based on one of their scores on three tests: the auditory
verbal learning test (AVLT) (memory), the word fluency test category
(executive function), and the adaptive tracking test (attention). Below
average cognitive functioning was defined as a score of ≤1 SD on at
least one of the tests. The reference values for the AVLT and word
fluency test were based on available norms.20 The mean score of the
adaptive tracking test was calculated from data from previously per-
formed studies in healthy elderly. Age and education level were taken
into account in the calculation of the score. Per cognitive domain, a
minimum of eight subjects showed below average functioning. Sub-
jects were excluded if they had a Clinical Dementia Rating scale (CDR)
score of >0, a mini-mental state examination (MMSE) score of <24 or
a Becks Depression Index-II (BDI-II) score of >13. Thus, subjects did
not have MCI (mild cognitive impairment) and did not have evidence
of progressive cognitive deterioration and it was therefore unknown
whether they were cholinergically deficient.
2.2 | Materials
In part A, HTL0009936 was administered as an IV solution and as an
oral solution. In the first treatment session, two subjects were dosed
0.1 mg HTL0009936 IV according to a sentinel procedure, followed
by two subjects dosed 1 mg HTL0009936 IV, followed by six subjects
dosed 10 mg HTL0009936 IV. The latter six subjects were adminis-
tered 49.2 mg HTL0009936 IV during the second treatment session,
83 mg HTL0009936 IV during the third treatment session, and 24 mg
HTL0009936 orally during the fourth treatment session to determine
the absolute oral bioavailability. The IV administration lasted up to
5 hours including the loading phase that varied per dose from
30 minutes to 2 hours. Safety, tolerability and PK data of part A was
used to find a well-tolerated dosing regimen for part B.
In part B, subjects received the following IV treatments in random
sequence (30 sequences were used): 13.5 mg HTL0009936 in order
to target an average concentration of HTL0009936 in plasma during
infusion of the maintenance dose (Cmean) of 25 ng/mL, 40 mg
HTL0009936 in order to target a Cmean of 75 ng/mL, 79.5 mg
HTL0009936 in order to target a Cmean of 150 ng/mL, placebo (saline
solution [sodium chloride 0.9%]), and physostigmine salicylate at a
rate of 1 mg/h for 50 minutes as positive comparator in combination
with an IV bolus administration of 0.2 mg glycopyrrolate bromide
(a peripheral muscarinic antagonist) administered immediately prior to
physostigmine administration.21 Physostigmine salicylate has reversed
temporary cognitive impairment in cognitively normal subjects that
was induced by administration of the anticholinergic drug scopol-
amine.22,23 The dual infusion of HTL0009936 in part B consisted of a
1 hour loading dose in order to reach the Cmean followed by a 4 hour
maintenance dose designed to maintain the target Cmean. As the infu-
sion regimens for the study drug and the positive comparator were
different, this study comprised a double-dummy condition.
2.3 | Safety and tolerability assessments
For parts A and B, all subjects underwent medical screening, including
assessment of medical history, physical examination, urine drug
screen, vital signs, ECG and safety laboratory measurements. During
treatment periods, safety was assessed by monitoring of adverse
events (AEs), vital signs, ECG, 5-hour Holter monitoring, and safety
chemistry and haematology blood sampling. Following a protocol
amendment, subjects were to be withdrawn when a rise of >40% in
systolic or diastolic blood pressure was measured as compared to the
mean of three pre-dose vital signs measurements and blood pressure
>150/90 mm Hg or when the blood pressure was >180/115 mm Hg
regardless of the change from baseline.
2.4 | Pharmacokinetic assessments
In part A, venous blood samples were collected pre-dose and post-
dose at different times during the different treatment sessions
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because of varying loading times. During all treatment sessions in
part B, PK was sampled according to the same schedule pre dose,
9–15 times within the first 8 hours after starting the administration
and at 12 and 24 hours post dose. Urine was collected continu-
ously for PK determination of HTL0009936 (Supplementary
Table S1).
All HTL0009936 plasma and urine concentrations were analysed
using an achiral liquid chromatography with tandem mass spectromet-
ric detection (LC–MS/MS) assay validated according to current guide-
lines. The detection range was 0.5–1000 ng/mL. Physostigmine
plasma concentrations were determined using a validated LC–MS/MS
assay with a quantification range of 0.10–10 ng/mL.
PK non-compartmental analysis was performed to determine the
maximum plasma concentration (Cmax), time to reach Cmax (Tmax), area
under the concentration–time curve from time of dosing to the last
quantifiable concentration measurement (AUC0-last), apparent terminal
elimination rate constant (lambda-z), AUC from time of dosing to
infinity (AUC0-∞), apparent terminal half-life (t½), total plasma clear-
ance (CLp), volume of distribution (Vd), absolute bioavailability (F),
amount unchanged in urine (Ae), fraction excreted in urine (fe) and
renal clearance (CLr). The AUC was calculated using the linear-
logarithmic trapezoidal method. Dose-proportionality was evaluated
by making pair-wise comparisons of the increase in dose and the
corresponding increase in exposure between dose levels. However, in
part A, the loading dose was not a constant fraction of the total dose.
Therefore dose-exposure proportionality of Cmax was determined by
relating the Cmax to the loading dose only. The software used for non-
compartmental analysis was R version 2.14.1.24
2.5 | Pharmacodynamic assessments
Only in part B of this study were PD assessments using both the
NeuroCart25 and the Cambridge Neuropsychological Test Automated
Battery (CANTAB)26 performed. The NeuroCart and CANTAB are test
batteries that include cognitive tests that can be used to examine
effects of CNS-active drugs on a wide range of cognitive domains.
NeuroCart and CANTAB tests have previously been shown to be
sensitive to cholinergic modulation.27–29 The NeuroCart also includes
neurophysiological measurements. Blood pressure and pulse rate
were considered both as safety and PD measurements.
The following NeuroCart tests were performed: the adaptive
tracking test measured attention and visuomotor coordination,25,30,31
the Milner maze test was used to evaluate spatial working memory,
learning and executive function,32 the n-back task was used to assess
(short-term) working memory,33–35 pupil size was measured to moni-
tor any drug effects on the sympathetic nervous system,36,37 synaptic
activity was assessed using electrophysiology and included resting
electroencephalography (EEG, power in delta, theta, alpha, beta and
gamma bands) and the event-related potentials (ERP) P300 and Mis-
match negativity (MMN).38,39 P300 is related to an early attention
process and is used as marker for attention40 and memory.40,41
MMN is related to central auditory processing and is used as a
marker for auditory memory.42 Visual verbal learning test (VVLT)
measured the whole scope of learning behaviour (i.e., acquisition,
consolidation, storage and retrieval),25 and a visual analogue scale
was used to evaluate subjective nausea. The Leeds Sleep Evaluation
Questionnaire (LSEQ) was used to assess changes in sleep quality.43
The following CANTAB tests were performed: the paired associates
learning test assessed visual memory, new learning and evaluated
episodic memory,44 the rapid visual information processing test was
used to measure sustained attention,45 and the spatial working mem-
ory test required retention and manipulation of visuospatial informa-
tion.46 Detailed task descriptions are provided in the Supplementary
Information.
PD tests were performed repeatedly and the timing was based
on PK characteristics of HTL0009936 measured in a previous study
in humans (maximum drug levels were measured in the CSF
1–2 hours after plasma Tmax). PD assessments were conducted at
baseline (pre-dose) and between 1 hour and 8 hours post treatment.
While the electrophysiological assessments ERPs MMN and P300,
and EEG and NeuroCart assessments were performed during
steady-state levels of HTL0009936, due to heavy study burden, the
three CANTAB assessments were performed at 5 hours post start
of treatment when infusion was stopped and plasma levels of
HTL0009936 were declining below target exposure levels. All post-
drug assessments for physostigmine were performed after infusion
was stopped at 50 minutes post dose when plasma levels were
declining and low.
2.6 | Statistics
No formal power calculations were performed to assess sample size in
part A. The sample size of ten subjects was considered adequate and
a compromise between minimizing exposure and the need to provide
sufficient data in order to find a well-tolerated dosing regimen for part
B and assess the bioavailability of oral HTL0009936. In part B, a sam-
ple size of 30 elderly subjects was defined to have 80% power to
detect a 1.53%-point difference in the adaptive tracking task, assum-
ing a standard deviation of 2.9, using a paired t-test with a two-sided
significance level of 0.05. Adaptive tracking was chosen to set the
sample size in this exploratory study because it was the task shown
previously to be most sensitive to cholinergic stimulation in studies of
donepezil.29
The PD analysis population per treatment session comprised all
subjects who had at least one post-baseline assessment of any param-
eter being analysed. Repeatedly measured PD variables (NeuroCart
tests, CANTAB tests, blood pressure and pulse rate) were analysed
with a mixed model analysis of covariance with treatment, period,
time and treatment by time as fixed factors, and subject, subject by
treatment and subject by time as random factors, and the average
baseline measurement as covariate. The single measured PD variables
were analysed with a mixed model analysis of variance with treatment
and period as fixed factors and subject as random factor and the base-
line measurement, if available, as covariate. The mean outcomes are
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presented as least square means (LSMs). Only PD data that was mea-
sured within 8 hours after starting the HTL0009936 administration
and within 2 hours after start of the physostigmine administration
were included in the analyses. PD tests performed within 2 hours
after start of physostigmine were adaptive tracking test, VAS nausea,
n-back test, pupillometry, EEG and ERP (P300 and MMN). The follow-
ing contrasts were calculated: HTL0009936 vs placebo and physostig-
mine vs placebo. All calculations were performed using SAS (version
9.4, SAS, Cary, NC).
3 | RESULTS
3.1 | Subjects
Subject demographics and baseline characteristics are summarized in
Table 1. A total of ten subjects participated in part A. No subjects
dropped out of part A after drug administration.
In part B, 33 subjects were enrolled. Eight subjects withdrew or
were withdrawn before the end of Part B for personal reasons (n = 4)
and safety reasons (n = 4) and (as per protocol) three of them were
replaced. Of the four subjects that were withdrawn due to safety
reasons, one subject presented with a raised serum creatinine after
completing the 13.5 mg dose before starting the second dosing day;
one subject completed three dosing days (placebo, physostigmine and
79.5 mg HTL0009936 respectively) before withdrawal due to a sec-
ond degree atrioventricular block on the Holter registration; one sub-
ject was withdrawn after completing the placebo and 13.5 mg
HTL0009936 dosing day because of ST-segment depression seen on
Holter registration; one subject completed the 40 mg, 79.5 mg, phy-
sostigmine and placebo dosing days before withdrawal due to ST seg-
ment depression on the Holter registration.
All treatment infusions were started by at least 28 subjects and
completed by at least 26 subjects (Figure 1).
3.2 | Safety and tolerability
In seven cases, study drug administration had to be prematurely
stopped due to a clinically significant rise in blood pressure. In part A
there was one such case. Of the six cases of clinically significant rises
in blood pressure in part B, one was related to administration of phy-
sostigmine, the remaining five were attributed to administration of
HTL0009936 (three of which were experienced in the same subject).
No subject was withdrawn from the study as a result of increased
blood pressure.
In both parts A and B, only mild or moderate self-limiting treat-
ment emergent adverse events (TEAEs) were reported and there were
no serious adverse events. The most frequently reported TEAEs in
part B following HTL0009936 administration were headache
(14 AEs), hyperhidrosis (6 AEs) and nausea (6 AEs).
One subject was withdrawn from the study because an
ST-depression was recorded during the Holter monitoring between
2 and 3 hours after starting the 13.5 mg HTL0009936 dose. There
were no relevant changes in ECG, physical examination findings or
laboratory values.
3.3 | Pharmacokinetics
The PK profile of HTL0009936 was well-characterized after IV infu-
sion and oral dosing in elderly subjects (Figure 2 and Tables 2–4). In
part B, targeted Cmean were reached. Systemic exposure after IV
dosing was dose-proportional over a wide dose range and showed an
inter-subject variability of 30%CV, irrespective of CYP2D6 interme-
diate or extensive metabolizer predicted phenotype. Plasma clearance
was 68–81 L/hr with a volume of distribution of 222–262 L consis-
tent with a short half-life (2.2–2.6 h). Renal clearance was a signifi-
cant route of elimination of unchanged HTL0009936 (CLr 8.0 L/h,
range 3.4–14.2 L/h) with about 10% of the dose excreted unchanged
after IV dosing. Absolute oral bioavailability was established to be
about 15% ranging from 8.7 to 27%. Variability after oral administra-
tion (50%CV) was higher compared to IV infusion and CYP2D6
predicted phenotype was found to be related to systemic exposure
and clearance of HTL0009936, with higher clearance and lower
exposure in EM subjects compared with IM subjects (Supplementary
Table S4).
Physostigmine plasma concentrations increased immediately after
dosing, with the mean Tmax at 50 minutes. It was rapidly eliminated
from plasma with a mean t½ of 0.37 hours (CV 31%) with observed
concentrations ≤ 1 ng/mL and typically < 0.5 ng/mL by 1.5 hours after
the start of infusion (see Supplementary Figure S5).
3.4 | Pharmacodynamics
Dose-related increases in both systolic and diastolic blood pressure
were observed following administration of 40 mg and 79.5 mg
HTL0009936 compared to placebo (Figure 3). There were no
TABLE 1 Summary demographics and baseline characteristics,
mean (SD)
Part A (n = 10) Part B (n = 33)
Age, years 70.2 (3.6) 70 (5.0)
Weight, kg 74.8 (12.3) 74.2 (8.7)
BMI, kg/m2 25.5 (3.7) 25.5 (2.5)
Gender, n (%)
Female 5 (50) 17 (52)
Male 5 (50) 16 (48)
CYP2D6 predicted phenotype, n (%)
Extensive metabolizer 10 (100) 27 (82)
Intermediate metabolizer 0 6 (18)
Cognitive score at screening < 1 SD, n (%)
Word fluency N/A 12 (36)
AVLT N/A 13 (39)
Adaptive tracking test N/A 14 (42)
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increases in systolic or diastolic blood pressure at the 13.5 mg dose.
The mean systolic blood pressure increased 3.87 mm Hg following
40 mg HTL0009936 (95% CI [0.70–7.05]) and 7.12 mm Hg after
79.5 mg HTL0009936 (95% CI [3.99–10.24]) compared with placebo.
Mean diastolic blood pressure increased 3.83 mm Hg following 40 mg
HTL0009936 (95% CI [1.64–6.01]) and 5.32 mm Hg after 79.5 mg
HTL0009936 (95% CI [3.18–7.47]) compared with placebo. Similarly,
there was a dose-related increase in heart rate. There were no
significant increases in pulse rate at the 13.5 mg and 40 mg
doses. Administration of 79.5 mg HTL0009936 resulted in
increased pulse rate of 4.75 bpm when compared with placebo (95%
CI [3.14–6.36]).
Overall, single doses of HTL0009936 showed no consistent acute
effects on measures of cognitive or neurophsyiological function as
F IGURE 1 Study design of part A (four-
treatment open label sequential design) and B
(five-treatment randomized, placebo and positive
comparator-controlled crossover design) and the
number of subjects that started and completed
the treatment
6 BAKKER ET AL.
measured by NeuroCart, CANTAB, EEG and ERPs compared with pla-
cebo (Supplementary Table S6). However, 13.5 mg HTL0009936
resulted in a mean increase in P300 maximum amplitude of 0.56 uV
over the Cz lead compared to placebo administration (95% CI
[0.139–0.971]), although similar increases were not observed at the
Fz and Pz leads (Figure 4). No clinically relevant effects were observed
on the VAS nausea scale and the LSEQ compared with placebo.
Physostigmine administration led to an improvement of
1.5%-poinst (95% CI 0.216–2.734) on the adaptive tracking test
performance within 2 hours post dose (Figure 4). No improvements in
adaptive tracking were observed with HTL0009936.
4 | DISCUSSION
The objective of the study was to assess safety, tolerability and PK in
elderly subjects and the effect of HTL0009936 on cognitive perfor-
mance in elderly subjects with below average cognitive function. In
part A, focusing on safety, tolerability and PK in normal healthy elderly,
HTL0009936 was administered IV over a dose range of 0.1 mg (over
30 min) up to 83 mg (over 5 h) and 24 mg orally. In part B, focusing on
safety, tolerability, PK and PD in elderly with below average cognitive
function, HTL0009936 was administered IV over a dose range of 13.5
to 79.5 mg and compared to placebo and physostigmine infusions in a
double dummy manner. The infusion in part B consisted of a 1 hour
loading dose in order to reach the target steady-state plasma concen-
tration followed by a 4 hour maintenance dose designed to maintain
the target steady-state concentration to ensure sustained exposure
within the CNS over the period of cognitive testing.
All doses of HTL0009936 were associated with mild to moderate
self-limiting TEAEs. Fewer subjects reported TEAEs after
HTL0009936 (50–56.7% of the subjects) than after physostigmine
(85.7% of the subjects) (Supplementary Information S3). The observed
small increases in systolic (3.87 mm Hg) and diastolic (5.32 mm Hg)
blood pressure and pulse rate (4.75 bpm) were dose-dependent and
consistent with expected effects of M1 mAChR stimulation on the
peripheral cardiovascular system.47 Importantly, the effects of blood
pressure and heart rate were acute, returning to normal soon after
HTL0009936 infusion was stopped suggesting there were no persis-
tent effects. Overall, HTL0009936 was considered safe and well-
tolerated in elderly subjects at exposures predicted to have central
physiological effects.
F IGURE 2 A. Concentration–time profiles of HTL0009936 single
IV infusion at 0.1 mg (n = 2), 1 mg (n = 2) and 10 mg in part A (mean
± SD for n = 6). B. Concentration–time profiles at 13.5, 40 and
79.5 mg HTL0009936 by dual IV infusion in part B (arithmetic mean ±
SD; n = 28–29). Profile truncated at 8 hours to show plateau during
maintenance dose
TABLE 2 Summary of HTL0009936 exposures after IV infusion in part A, mean (%CV) or [range]
Dose (mg)
Observed Cmean




(hr.ng/mL) t½ (hr) CLp (L/hr) CLr (L/hr)
10a n/a 0.50 [0.33–0.58] 59.5 (35) 120 (24) 124 (24) 2.2 (12) 81 (24) 8.7 (27)
49.2b 97 (22) 0.50 [0.17–5.5] 125 (33) 684 (24) 691 (24) 2.3 (35) 71 (24) 7.2 (41)
83c 172 (17) 2.0 [2.0–3.0] 197 (20) 1130 (17) 1140 (16) 2.4 (25) 73 (17) 7.8 (25)
Geometric mean and (geometric %CV) except Tmax median [minimum  maximum] for n = 6 per dose except n = 5 at 83 mg. AUC0-∞, area under the
plasma concentration–time curve from zero extrapolated to infinity; AUC0–24, area under the plasma concentration–time curve from zero to 24 hours post
dose; Cmax, maximum plasma concentration; Cmean, mean plasma concentration during maintenance infusion; CLp, total plasma clearance; CLr, renal
clearance; Tmax, time to Cmax; t½, apparent terminal half-life.
a10 mg over 0.5 hr at 33.2 mL/h.
b14.1 mg over 0.5 hr at 47 mL/hr + 35.1 mg over 4.5 hr at 13 mL/hr.
c43 mg over 2 hr at 64.8 mL/hr + 40 mg over 3 hr at 40.2 mL/hr.
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The PK of HTL0009936 were well-characterized up to single
doses of 83 mg. IV infusion in part B resulted in stable and sustained
exposure of HTL0009936. The PK variability after IV administration
was lower than after oral administration (i.e., 30% vs 50%
respectively).
Overall, no definitive positive or negative PD effects were
observed on behavioural and electrophysiological biomarkers of
cognitive function. Potential reasons for a lack of a clear PD effect are
discussed below, which impacts the conclusions that can be drawn on
the PD effects of HTL0009936. However, HTL009936 showed a
selective pro-cognitive effect as shown by an increase in P300
amplitude at the 13.5 mg doses, suggesting an improvement in early
attentional processing. However, these data need to be interpreted
with caution as the effects were only noted at the Cz lead, and not at
the Fz lead (leads with the greatest signal change with P300
generated using a passive odd ball task).
In order to reduce the ceiling effects that cognitive tests have in
healthy optimal cognitive functioning subjects, we aimed to investi-
gate HTL0009936 in a study population in which the ceiling effects
could be expected to be more limited, based on lower cognitive test
scores. The percentage of subjects with impairments were 39% for
memory, 36% for executive function and 42% for attention. One limi-
tation of using this approach is that not all subjects were impaired on
all tests and the percentage of subjects impaired in any one test or
on all tests was low. This may have led to a variable cognitive baseline
for the study population. Hence detecting drug effects may have been
difficult for some domains of cognition. Alternatively, as subjects had
no evidence of cholinergic deficiency, it is possible that they were not
an appropriate population for study of this mechanism of action.
In addition to the potential limitation discussed above, the study
was powered to detect a significant change in the adaptive tracking
and therefore not to detect statistically significant changes in
EEG/ERP or other cognitive tests in which either smaller treatment
effects or larger variability could have been present. In addition, multi-
ple PD assessments were not performed at the optimal time of target
concentration of HTL0009936 (for the CANTAB tests performed at
5 h post dose) and physostigmine (for EEG and all cognitive tests per-
formed after 1 h post dose). This was due to stopping the infusion of
HTL0009936 at 5 hours and physostigmine at 50 minutes and the
rapid drop in exposures of both drugs post cessation of infusion dur-
ing the time of these assessments. The main reason for the latter was
concerns with side effects associated with prolonged exposure to
physostigmine. Additionally, subject discontinuation in the study, due
to the significant burden of the number of assessments, required a
change to the protocol in order to reduce the frequency of CANTAB
tests. These limitations in the execution of the study are likely to have
contributed to the lack of clear PD effects on the neurophysiological
and neurocognitive tests after administration of HTL0009936 or phy-
sostigmine. However, physostigmine was associated with a significant
but small improvement in adaptive tracking (reflecting psychomotor
function and sustained attention). The improvement in adaptive track-
ing and the lack of effect on other tests may be due to the adapting
tracking being performed close to the time when the physostigmine
infusion was stopped (i.e., 10 min after infusion was stopped). As this
study was powered on the adaptive tracking test, it is likely that this is
a cholinergic relevant pharmacological effect of physostigmine and
supports previous studies that have similarly shown positive effects of
a cholinesterase inhibitor galantamine.35 The absence of an effect on
TABLE 3 Oral PK of HTL0009936 at 24 mg, mean (%CV) or [range] for n = 6
Dose (mg) Tmax (hr) Cmax (ng/mL) AUC0–24 (h.ng/mL) AUC0-∞ (hr.ng/ml) t½ po (hr) Fpo (%)
a
24 1.0 [0.50–1.5] 14.1 (49) 44.1 (48) 47.2 (41) 2.4 (28) 14.8 (44) [8.7–27]
Geometric mean and (geometric %CV) except Tmax median [minimum  maximum] for n = 6. AUC0-∞, area under the plasma concentration–time curve
from zero extrapolated to infinity; AUC0–24, area under the plasma concentration–time curve from zero to 24 hours post dose; Cmax, maximum plasma
concentration; Fpo, oral bioavailability and [minimum  maximum]; Tmax, time to Cmax; t½ po, apparent terminal half-life after oral administration.
aOral bioavailability estimated in comparison with 10 mg IV single infusion.
TABLE 4 Summary table of HTL0009936 exposures in part B (CYP2D6 EM and IM subjects combined), mean (%CV) and [range]
Dose (mg)a Cmean (ng/mL)




(hr.ng/mL) t½ IV (hr) CLp (L/hr) CLr (L/hr)
13.5 (4.5 + 9) 27.1 (20) 1.0 [0.52–5.1] 33.8 (21) 192 (27) 197 (26) 2.2 (28) 69 (26) 8.6 (23)
40 (13.3 + 26.7) 78.2 (18) 1.0 [0.58–5.3] 97.6 (21) 550 (24) 564 (24) 2.3 (33) 71 (24) 8.2 (27)
79.5 (26.5 + 53) 166 (20) 1.1 [0.83–5.6] 203 (20) 1200 (31) c 1170 (25) 2.6 (27) 68 (25) 7.3 (30)
Geometric mean and (geometric %CV) except Tmax median [minimum  maximum] for n = 25–28 observations excluding subjects where infusion was
stopped early or interrupted. AUC0-∞, area under the plasma concentration–time curve from zero extrapolated to infinity; AUC0–24, area under the plasma
concentration–time curve from zero to 24 hours post dose; Cmax, maximum plasma concentration; Cmean, mean plasma concentration during 4 hour
maintenance infusion; CLp, total plasma clearance; CLr, renal clearance; Tmax, time to Cmax; t½ IV, post-infusion intravenous apparent half-life;
aLoading dose (1 hr at 83.3 mL/hr) + maintenance dose (4 hr at 41.7 mL/hr).
bSteady-state concentration maintained between 1 and 5 hours after the start of dosing.
cIncludes a subject with a large value of AUC0-t due to limited available PK sampling times but for whom a value of AUC0-∞ could not be estimated,
therefore the group mean value of AUC0-t was greater than AUC0-∞.
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adaptive tracking performance during HTL0009936 exposure based
on visual inspection of the graphs might be due to specificity of the
cognitive processes modulated by M1 receptor modulation. It is possi-
ble psychomotor/attentional processes are less affected whereas
memory is more affected by M1 receptor modulation. In support, a
study with the M1 agonist GSK1034702 showed improvement in epi-
sodic memory but not psychomotor speed or attention.48 Further-
more, preclinical studies with HTL0009936 showed reversal of
scopolamine-induced impairment in the novel object recognition and
passive avoidance tests of memory and improvement in working
memory in aged Beagle dogs.49 On the other hand, the M1/M4 musca-
rinic antagonist biperiden led to a decrease in performance in the
adaptive tracking task at dose levels that did not lead to clinically
overt (subjective or objective) sedation (results in preparation to be
published). Given the limitations discussed, which may have impacted
the ability of HTL0009936 to exert effects of cognitive and neuro-
physiological function, no clear conclusions can be drawn with regard
to the PD effects of HTL0009936 in this study. This would require
furtherinvestigationinanappropriatelydesignedandadequatelypowered
study.
In summary, this safety, tolerability, PK and exploratory PD study
of HTL0009936 showed that the drug had well-characterized PK and
was generally well-tolerated in the dose range studied in elderly sub-
jects. The incidence of adverse events was mild and dose-related. No
clear PD effects of HTL0009936 could be observed, except a poten-
tial increase (i.e., improvement) in P300 amplitude, a measure of cog-
nitive function, and a lack of effect of attention and psychomotor
speed as measured by the adaptive tracking test. However, overall, no
conclusions can be drawn with regard to positive or negative effects
of HTL0009936 on neurophysiological and neurocognitive function,
given the limitations in the execution of this study, including multiple
cognitive tests performed at suboptimal exposures which may have
impacted the ability to detect a drug effect. While the PD effects of
HTL0009936 require further investigation, the good safety profile
of HTL0009936 supports further safety and PD investigation in
patients with AD and other dementias.
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